Edition:
United Kingdom

Chemed Corp (CHE.N)

CHE.N on New York Stock Exchange

260.79USD
2:31pm GMT
Change (% chg)

$-1.37 (-0.52%)
Prev Close
$262.16
Open
$263.97
Day's High
$263.97
Day's Low
$260.79
Volume
1,094
Avg. Vol
31,585
52-wk High
$264.75
52-wk Low
$163.94

Latest Key Developments (Source: Significant Developments)

Chemed reaches final agreement to end civil litigation & false claims act brought by U.S. DOJ in May 2013​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Chemed Corp ::Chemed - Reached final agreement to end civil litigation and false claims act brought by U.S. Department of Justice in May 2013​.Chemed Corp - ‍In connection with settlement, Vitas has also agreed to a corporate integrity agreement with office of inspector general​.Chemed - ‍Total settlement estimated at $85 million pre-tax & compares to $90 million pre-tax ($55.5 million after-tax) of estimated settlement cost recorded in Q2.Chemed Corp - ‍Company will fund the settlement with existing cash balances and its bank credit facility​.  Full Article

Chemed reports Q3 earnings per share $2.13
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Chemed Corp :Chemed reports third-quarter 2017 results.Sees FY 2017 adjusted earnings per share $8.35 to $8.40 excluding items.Q3 adjusted earnings per share $2.15.Q3 gaap earnings per share $2.13.Q3 earnings per share view $2.01 -- Thomson Reuters I/B/E/S.Chemed Corp - qtrly ‍revenue increased 6.3% to $417 million​.Q3 revenue view $413.8 million -- Thomson Reuters I/B/E/S.Chemed Corp qtrly ‍vitas net patient revenue of $289 million, an increase of 2.2%​.Chemed Corp - ‍roto-rooter is forecasted to achieve full-year 2017 revenue growth of 13% to 14%​.Chemed Corp - ‍adjusted ebitda margin for roto-rooter​ for 2017 is estimated at 22.5%.Chemed Corp - ‍revenue growth for vitas in 2017, prior to medicare cap, is estimated to be in range of 2% to 3%​.Chemed Corp - ‍admissions and average daily census for vitas in 2017 are estimated to expand approximately 2% to 3%​.Chemed Corp - ‍full-year 2017 adjusted ebitda margin for vitas, prior to medicare cap, is estimated to be 15.0% ​.  Full Article

Chemed Q4 GAAP earnings per share $1.94
Wednesday, 15 Feb 2017 

Chemed Corp : Chemed reports fourth-quarter 2016 results . Q4 adjusted earnings per share $2.10 . Q4 GAAP earnings per share $1.94 . Q4 revenue $403 million versus I/B/E/S view $409.9 million . Chemed Corp says average revenue per patient per day in quarter was $191.15, which is 3.0% below prior-year period . Q4 earnings per share view $2.10 -- Thomson Reuters I/B/E/S . Chemed Corp says Q4 of 2016 gross margin was 24.1%, which is essentially equal to Q4 of 2015 . Chemed Corp says Roto-Rooter's gross margin in quarter was 46.9%, a 38 basis point decline when compared to Q4 of 2015 . Chemed Corp sees revenue growth for vitas in 2017, prior to Medicare cap, is estimated to be in range of 4% to 5% . Chemed Corp says Roto-Rooter is forecasted to achieve full-year 2017 revenue growth of 3% to 4% . Says admissions and average daily census in 2017 are estimated to expand approximately 3% to 4% . Chemed Corp says revenue growth for vitas in 2017, prior to Medicare cap, is estimated to be in range of 4% to 5% . Says currently estimating $5.0 million for Medicare cap billing limitations in 2017 . Chemed Corp sees full-year 2017 adjusted earnings per diluted share excluding items estimated to be in range of $7.80 to $8.00 .FY2017 earnings per share view $7.82 -- Thomson Reuters I/B/E/S.  Full Article

Chemed Corporation increases quarterly dividend 8.3 pct
Friday, 5 Aug 2016 

Chemed Corp : Chemed Corporation increases quarterly dividend 8.3% .Board of Directors has declared a quarterly cash dividend of 26-cents per share on company's capital stock.  Full Article

Chemed Corp Q2 shr $1.48
Monday, 25 Jul 2016 

Chemed Corp : Sees roto-rooter business FY 2016 revenue up 4 to 5 percent . Says roto-rooter business 2016 adjusted ebitda margin is estimated in range of 20.0% to 21.0% . Quarter 2016 results . Q2 adjusted earnings per share $1.80 . Q2 GAAP earnings per share $1.48 . Sees fy 2016 adjusted earnings per share $7.97 to $8.12 excluding items . Q2 earnings per share view $1.72 -- Thomson Reuters I/B/E/S . Raises full-year earnings guidance . Says full-year 2016 revenue growth for vitas, prior to medicare cap, is estimated to be in range of 1.5% to 3.0% .Qtrly net patient revenue of $279 million, an increase of 0.8%.  Full Article

Chemed Corp reports second-quarter 2016 results
Monday, 25 Jul 2016 

Chemed Corp :Chemed reports second-quarter 2016 results.  Full Article

BRIEF-Chemed reaches final agreement to end civil litigation & false claims act brought by U.S. DOJ in May 2013​

* Chemed - Reached final agreement to end civil litigation and false claims act brought by U.S. Department of Justice in May 2013​